Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.

Prager, G.; Oehler, L.; Gerger, A.; Mlineritsch, B.; Andel, J.; Petzer, A.; Wilthoner, K.; Sliwa, T.; Pichler, P.; Winder, T.; Heibl, S.; Gruenberger, B.; Laengle, F.; Hubmann, E.; Korger, M.; Pecherstorfer, M.; Djanani, A.; Neumann, H.; Philipp-Abbrederis, K.; Wöll, E.; Trondl, Robert; Arnold-Schrauf, Catharina; Eisterer, W.

doi:10.1016/j.ejca.2020.11.003

Public

Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.

Shared by NobleBlocks on Dec 6, 2020 • 12:00 AM UTC

Authors:

G. Prager

L. Oehler

A. Gerger

Abstract

BACKGROUND Pancreatic cancer (PC) ranks among the deadliest malignancies worldwide. In the MPACT study, first-line nab-paclitaxel plus gemcitabine (nab-P/G) demonstrated activity (median overall survival [OS], 8.7 months) and tolerability in patients with metastatic PC (mPC). However, the clinical e...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!